Risk stratification and multi-omics reveal RAD51 inhibition as a radiosensitizing strategy in triple-negative breast cancer
BackgroundTriple-negative breast cancer (TNBC) is a highly aggressive subtype characterized by significant inter- and intra-tumoral heterogeneity. Its varied response to radiotherapy limits clinical outcomes, yet the underlying molecular determinants r…